Autolus Therapeutics plc
NASDAQ:AUTL · NASDAQ Global Select
+$0.01 today
Vol 0.83M · Avg 1.60M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $130.9M |
| Short-term Investments | $98.5M |
| Receivables | $86.3M |
| Inventory | $33.2M |
| Other Current | $19.9M |
| Total Current Assets | $368.8M |
| PP&E (Net) | $134.5M |
| Intangible Assets | $19.0M |
| Tax Assets | $3.6M |
| Other Non-current | $1.2M |
| Total Non-current Assets | $158.2M |
| Total Assets | $527.1M |
Analysis
Selected assets total $527.1M for Latest. The largest visible component is PP&E (Net) at $134.5M, about 25.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.1M -54.2% | $227.4M -5.1% | $239.6M -37.4% | $382.4M +23.2% | $310.3M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $196.6M -45.5% | $360.6M | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $75.8M +57.1% | $48.2M +4507.4% | $1.0M -96.4% | $29.0M +42511.8% | $68.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $33.2M +702.5% | $4.1M | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.9M -7.2% | $5.3M -79.6% | $26.1M +1188.4% | $2.0M -92.7% | $27.8M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $435.9M -34.0% | $660.9M +140.1% | $275.3M -35.3% | $425.8M +22.7% | $347.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $128.5M +22.3% | $105.1M +9.8% | $95.7M +63.7% | $58.4M +11.7% | $52.3M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $19.8M +60.1% | $12.4M | $0 | $0 -100.0% | $65.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $3.6M +9.9% | $3.2M +5.7% | $3.1M +47.5% | $2.1M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $1.3M +13.1% | $1.1M -16.9% | $1.4M -66.0% | $4.0M -35.6% | $6.2M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $153.2M +25.7% | $121.8M +21.7% | $100.1M +55.2% | $64.5M +10.1% | $58.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $589.1M -24.7% | $782.7M +108.5% | $375.4M -23.4% | $490.3M +20.9% | $405.6M | $13.3B | $11.9B | $10.6B |
| Account Payables | $3.1M +56.6% | $2.0M +1811.7% | $103.0K -80.6% | $531.0K +23.2% | $431.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $14.6M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $3.6M | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $55.8M +135.8% | $23.7M +54.7% | $15.3M +44.6% | $10.6M +6508.8% | $160.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $73.4M +20.9% | $60.7M +35.8% | $44.7M -3.5% | $46.4M +62.4% | $28.6M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $270.2M | $0 | $0 | $0 -100.0% | $47.0M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $477.0K -99.8% | $245.0M +43.1% | $171.3M +35.9% | $126.0M +98350.0% | $128.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $337.5M +14.5% | $294.7M +34.4% | $219.2M +50.9% | $145.2M +128.0% | $63.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $410.9M +15.6% | $355.4M +34.7% | $263.9M +37.7% | $191.6M +107.7% | $92.2M | $14.7B | $3.7B | $9.6B |
| Common Stock | $12.0K +0.0% | $12.0K +50.0% | $8.0K +0.0% | $8.0K +100.0% | $4.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.4B -26.2% | -$1.1B -25.1% | -$878.6M -31.1% | -$670.2M -28.5% | -$521.3M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$5.4M +81.6% | -$29.2M -0.6% | -$29.0M +25.5% | -$38.9M -360.2% | -$8.5M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 -100.0% | $118.0K +0.0% | $118.0K +0.0% | $118.0K +11800100.0% | -$1 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $178.1M -58.3% | $427.3M +283.3% | $111.5M -62.7% | $298.7M -4.7% | $313.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $351.6M +568.0% | $52.6M -0.6% | $53.0M +118.4% | $24.3M -64.3% | $68.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | $247.5M +241.6% | -$174.8M +6.3% | -$186.6M +47.9% | -$358.2M -47.8% | -$242.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$848.51M
Solid Biosciences Inc.
NASDAQ:SLDB
$590.95M
Annexon, Inc.
NASDAQ:ANNX
$585.79M
Aura Biosciences, Inc.
NASDAQ:AURA
$399.32M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$351.06M
Benitec Biopharma Inc.
NASDAQ:BNTC
$316.28M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$271.44M
Quantum-Si incorporated
NASDAQ:QSI
$194.84M
ADC Therapeutics S.A.
NYSE:ADCT
$136.09M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AUTL have?
Autolus Therapeutics plc (AUTL) reported $104.13M in cash and equivalents in fiscal 2025.
How much debt does AUTL carry?
Autolus Therapeutics plc (AUTL) reported $351.59M of total debt, with net debt of $247.45M.
Explore More
Continue the stock analysis
Jump to another research area for this company.